B細胞による免疫応答調節とその臨床的意義 : B細胞を標的とした自己免疫疾患の治療
スポンサーリンク
概要
- 論文の詳細を見る
The levels and types of immune responses are determined dependent on the extent of pathogen invasion, reactions to antigens mediated by macrophage-dendritic cells, T cells and antibodies. Recently, accumulating evidence suggests that B cells also play an important role in the regulation of immune responses. Here we have made a review to present a role of B cells in determining the level of immune responses and discussed about the clinical significance of B cell-targeted therapy in patients with autoimmune diseases. Type 1 diabetes is a T cell-mediated autoimmune disease characterized by the destruction of insulin-producing pancreatic A3 cells. We and other groups have elucidated that B cells play a critical role in the development of insulitis and diabetes, as B-cell-deficient NOD mice are protected from developing type 1 diabetes. B cells are essential for the T cell receptor clonotype spreading of islet-infiltrating T cells, indicating that B cells may play a role in determining the level of immune responses by antigen presentation to antigen specific T cells. There are now numerous case reports and small series of clinical trials regarding rituximab therapy in autoimmune diseases, such as refractory autoimmune hemolytic anemia, IgM antibody-associated polyneuropathy, systemic lupus erythematosus and rheumatoid arthritis. Rituximab is a genetically engineered chimeric anti-CD 20 monoclonal antibody that is approved for the treatment of lymphoma. CD20 is a B-cell surface antigen that is expressed only on pre B and mature B cells. Thus, rituximab causes a selective transient depletion of the CD20+ B -cell subpopulation . Rationale and strategy for targeting B cells in the treatment of autoimmune diseases consist of the inhibition of antigen-presentation and co-stimulation that induces T cell expansion and activation. Further careful mechanistic studies are required to develop therapies in patients with autoimmune diseases.
- 福岡医学会,Fukuoka Medical Associationの論文
- 2005-04-25
著者
関連論文
- 同種骨髄移植後移植片対宿主病に対するFK506投与2例に認めた糖代謝異常
- 非自己免疫性劇症1型糖尿病と考えられた5例の臨床的検討
- ナテグリニドによる遷延性重症低血糖の1例
- ペリンドプリルの軽症高血圧・早期腎症合併糖尿病患者に対する有効性 : 高血圧非合併糖尿病患者との比較
- 日本人糖尿病患者におけるβ3アドレナリン受容体遺伝子ミスセンス変異と肥満,高血圧,内臓脂肪症候群との関連
- 抗リン脂質抗体症候群に合併した網膜血管閉塞症の2例
- 逆行性の感染様式であることが推測された単純ヘルペスウイルス1型(HSV-1)の家族内感染
- 58)左房内巨大血栓による心原性脳塞栓症を繰り返し、死の転帰をとった一例(日本循環器学会第65回中国四国地方会)
- B細胞による免疫応答調節とその臨床的意義 : B細胞を標的とした自己免疫疾患の治療
- 糖尿病に合併する感染症(第14回)カンジダ
- P-1056 外来患者に対するインスリン・GLP-1受容体作動薬自己注射 : 継続指導への取り組み(一般演題 ポスター発表,糖尿病,Enjoy Pharmacists' Lifestyles)